Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxybutynin for Post-surgical Bladder Pain and Urgency
NCT03952299Phase 3Recruiting
- Sponsor
- University of California, Davis
- Start
- Sep 2021
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of oxybutynin in postoperative pain (2 arms), sponsored by University of California, Davis. Primary endpoints: Urgency Scores at 6 weeks, Pain Scores at 6 weeks and 1 more. Started Sep 2021; status: recruiting.
02
Drugs
oxybutynin
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT03952299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03952299.